CliffBio
small molecule

ALENDRONATE SODIUM

ALENDRONATE SODIUM

Loss of exclusivity—loss of exclusivity
CompanyNovitium Pharma →See this company's full patent-cliff portfolio

Drug detail

Brand nameALENDRONATE SODIUM
Active ingredientALENDRONATE SODIUM
StrengthEQ 70MG BASE/75ML
Dosage formSOLUTION
RouteORAL
ModalitySmall molecule
FDA approvalMay 2023
Marketing statusRX

More from Novitium Pharma

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.